UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 22, 2007

HEMACARE CORPORATION

(Exact name of registrant as specified in its charter)

California	000-15223	95-3280412
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation or organization)	File Number)	Identification No.)
15350 Sherman Way, Suite 350  Van Nuys, California		91406
(Address of principal executive offices)		(Zip Code)
(Registrant’s telephone number, including area code):   818-226-1968

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

On March 22, 2007, HemaCare Corporation issued a press release announcing financial results for the fourth quarter and full year of 2006.  A copy is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

On March 22, 2007, HemaCare Corporation held an investor conference call discussing the financial results for the fourth quarter and full year of 2006. A transcript of the conference call is attached to this report as Exhibit 99.2 and is incorporated herein by reference.

Subsequent to the press release and conference call, the Company determined that current liabilities as of December 31, 2006 should have been reported as $8,280,000 instead of $8,669,000 as reported in the press release. In addition, long-term liabilities should have been reported as $914,000 instead of $525,000 as reported in the press release. Finally, the amount of working capital discussed during the conference call should have been $2.2 million as of December 31, 2006, instead of $1.8 million.

The information in this Current Report on Form 8-K, including the exhibits, will not be treated as “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934 (the “Exchange  Act”) or otherwise subject to the liabilities of that section.  This information will not be incorporated by reference into a filing under the Securities Act of 1933, or into another filing under the Exchange Act, unless that filing expressly refers to specific information in this report.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit Number	Description
99.1	Press Release dated March 22, 2007.
99.2	Transcript of the conference call conducted by HemaCare Corporation on March 22, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	March 28, 2007	HEMACARE CORPORATION
		By:	/s/ Robert S. Chilton
			Robert S. Chilton
			Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release dated March 22, 2007.
99.2	Transcript of the conference call conducted by HemaCare Corporation on March 22, 2007.